Nektar Therapeutics (NKTR) Misses Q1 EPS by 4c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $75.25 +2.12%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
SQZB, ARDS, MDRX, More
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
SQZB, ARDS, MDRX, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $14.49 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Assumes Knife River Corp. (KNF) at Buy
- Nvidia Q2 preview: a beat is a fail, a blowout is base case
- Nektar's atopic dermatitis drug data published in The Lancet
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
